AusCann (ASX:AC8) has announced it has been granted an Australian manufacturing licence authorising the manufacture and supply of medicinal cannabis under the Narcotic Drugs Act 1967.
The company is now one of a few Australian based medicinal cannabis companies that can cultivate, manufacture and supply Australian produced cannabinoid medicines to patients.
The new licence follows previously granted Australian cultivation licences for the company’s site in Western Australia and in Tasmania through its strategic partnership with Tasmanian Alkaloids.
In combination with the company’s existing cultivation licences, the recently granted manufacturing licence strongly positions AusCann with one of the first complete and fully Australian supply chains to provide medicinal cannabis products to patients.
According to managing director, Elaine Darby, “AusCann was established to provide high quality, cost effective cannabinoid medicines for Australian patients. Securing both a cultivation and a manufacturing licence will enable us to achieve this aim and demonstrates our leadership position in the industry.
"In preparation for the supply of Australian produced medicines, AusCann has been actively engaged with the medical community through its educational and medical outreach program. AusCann has made excellent progress raising awareness and support amongst the medical community and is well positioned to become the supplier of choice for Australian patients.”